title: Prospective randomized comparison of sirolimus- versus paclitaxel-eluting stents for the treatment of acute ST-elevation myocardial infarction: pROSIT trial.
abstract: OBJECTIVE
  The aim of this study was to compare effectiveness of the Sirolimus- (SES) and Paclitaxel-eluting stent (PES) in primary angioplasty for acute ST-elevation myocardial infarction (STEMI).
  
  
  BACKGROUND
  It has been reported that SES and PES have been more effective than bare-metal stents in reducing restenosis and cardiac events in a broad range of patients with coronary artery disease. However, it is unknown whether there may be differences between these two drug-eluting stents in terms of efficacy in the setting of acute STEMI.
  
  
  METHODS
  Acute STEMI patients (n = 308) undergoing primary angioplasty were randomly assigned to SES (n = 154) or PES (n = 154) deployment. The routine angiographic follow-up was performed at 6 months and clinical follow-up data was obtained at 12 months. The primary end point was major adverse cardiac events (MACE) including death, reinfarction, stent thrombosis, and target lesion revascularization (TLR) at 12 months.
  
  
  RESULTS
  The baseline clinical, angiographic, and procedural characteristics were similar between the 2 groups. Two patients (all from the PES group) experienced stent thrombosis (1 acute and 1 subacute). The SES group revealed lower in-segment restenosis (5.9% vs. 14.8%, P = 0.03) and in-segment late loss (0.09 +/- 0.45 vs. 0.33 +/- 0.68 mm, P = 0.002) than PES group on follow-up angiography. Twelve-month TLR rates (2.6% vs. 6.5%, P = 0.17) were similar between two groups. MACE rates were lower in the SES group than in the PES group, but it did not reach statistical significance (5.8% vs. 11.7%, P = 0.07).
  
  
  CONCLUSIONS
  In the setting of primary angioplasty for STEMI, there were no statistically significant differences between the SES and the PES in terms of 12-month MACE. However, binary angiographic in-segment restenosis and in-segment late loss were significantly lower in the SES group.
authors.affiliation: Cardiovascular Center in Chungnam National University Hospital, Chungnam National University, Daejeon, Korea.
authors.forename: Jae-Hwan
authors.initials: JH
authors.lastname: Lee
authors.forename: Hyun-Sook
authors.initials: HS
authors.lastname: Kim
authors.forename: Seung-Whan
authors.initials: SW
authors.lastname: Lee
authors.forename: Jae-Hyeong
authors.initials: JH
authors.lastname: Park
authors.forename: Si-Wan
authors.initials: SW
authors.lastname: Choi
authors.forename: Jin-Ok
authors.initials: JO
authors.lastname: Jeong
authors.forename: Yoonhaeng
authors.initials: Y
authors.lastname: Cho
authors.forename: Naehee
authors.initials: N
authors.lastname: Lee
authors.forename: Kyoung-Suk
authors.initials: KS
authors.lastname: Rhee
authors.forename: Jae-Ki
authors.initials: JK
authors.lastname: Ko
authors.forename: In-Whan
authors.initials: IW
authors.lastname: Seong
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D015331:Cohort Studies; D054855:Drug-Eluting Stents / Q000009:adverse effects; D005260:Female; D006083:Graft Occlusion, Vascular / Q000000981:diagnostic imaging / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000628:therapy*; D017239:Paclitaxel / Q000008:administration & dosage*; D011859:Radiography; D016037:Single-Blind Method; D020123:Sirolimus / Q000008:administration & dosage*; D016896:Treatment Outcome; D050257:Tubulin Modulators / Q000008:administration & dosage*
chemical_list: D007166:Immunosuppressive Agents; D050257:Tubulin Modulators; D017239:Paclitaxel; D020123:Sirolimus